Company: AZN
Filing Date: 2025-09-29
Form Type: 6-K
Source: 0001104659-25-094039
Chunk: 49

Company: ASTRAZENECA PLC
Filing Date: 2025-09-29
Form: 6-K
Chunk 49
---
 behalf all of its powers as a member provided that if two or more representatives purport to vote in respect of the same shares:

•

if they purport to exercise the power in the same way as each other, the power is treated as exercised in that way; and

•

in other cases, the power is treated as not exercised.

<div align='center'>37</div>

TABLE OF CONTENTS

Nominated Persons

Any person to whom this Notice of General Meeting is sent who is a person nominated under section 146 of the Companies Act 2006 to enjoy information rights (

#### “Nominated Person”
) may have a right, under an agreement between him or her and the member by whom he or she was nominated, to be appointed (or to have someone else appointed) as a proxy for the General Meeting. If a Nominated Person has no such proxy appointment right or does not wish to exercise it, he or she may, under any such agreement, have a right to give instructions to the member as to the exercise of voting rights.

The statement of the rights of members in relation to the appointment of proxies above does not apply to Nominated Persons. The rights described above can only be exercised by members of the Company.

Email communications

You may not use any email address provided in this Notice to communicate with the Company for any purposes other than those expressly stated.

Voting Results

The results of the voting at the General Meeting will be announced through a Regulatory Information Service and will appear on our website at www.astrazeneca.com as soon as reasonably practicable following the conclusion of the General Meeting.

Total voting rights

At 6:00 p.m. (UK time) on 25 September 2025 (being the Latest Practicable Date prior to the publication of this Notice), the Company’s issued share capital consisted of 1,550,701,945 ordinary shares, carrying one vote each. Therefore, the total voting rights of the Company at 6:00 p.m. (UK time) on 25 September 2025 were 1,550,701,945.

Documents available for inspection

Copies of the proposed New Articles and the Existing Articles, marked up to show the proposed changes, are available from the date of this document for inspection on the National Storage Mechanism at https://data.fca.org.uk/#/nsm/nationalstoragemechanism and on the Company’s website at https://www.astrazeneca.com/investor-relations/shareholder-information.html#202